Matthew McMenemy is an Ophthalmology physician affiliated with Berkeley Eye Center. OpenAlex indexes 12 publications with 468 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3515 Town Center Blvd S
Sugar Land, TX 774791285
Telephone
281-277-8400Provider last certified this registry record 27 Oct 2020.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bausch & Lomb Americas Inc.Program year202535 payments$27,723openpaymentsdata.cms.gov ↗
- Alcon Vision LLCProgram year202520 payments
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial
American Journal of Ophthalmology
2019 - Evaluation of the efficacy and safety of latanoprost 0.005% without benzalkonium chloride and its noninferiority to latanoprost 0.005% with benzalkonium chloride in patients with open-angle glaucoma and ocular hypertension2019
- A Randomized Trial of Fixed-Dose Combination Brinzolamide 1%/Brimonidine 0.2% as Adjunctive Therapy to Travoprost 0.004%
American Journal of Ophthalmology
2016 - Demographic Subgroup Analysis in a Study Comparing the Additive Effect of Brinzolamide 1%/Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension Treated with TRAVATAN Z® (NCT01937299)2015
- Phase 3 Randomized 3-Month Trial with an Ongoing 3-Month Safety Extension of Fixed-Combination Brinzolamide 1%/Brimonidine 0.2%
Journal of Ocular Pharmacology and Therapeutics
2013
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”